PTI-1

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
PTI-1
PTI-1 structure.png
Legal status
Legal status
Identifiers
  • N,N-diethyl-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)ethanamine
CAS Number
ChemSpider
UNII
Chemical and physical data
FormulaC21H29N3S
Molar mass355.54 g·mol−1
3D model (JSmol)
  • CCCCCN1C=C(C2=NC(CN(CC)CC)=CS2)C3=CC=CC=C31.Cl
  • InChI=1S/C21H29N3S.ClH/c1-4-7-10-13-24-15-19(18-11-8-9-12-20(18)24)21-22-17(16-25-21)14-23(5-2)6-3;/h8-9,11-12,15-16H,4-7,10,13-14H2,1-3H3;1H
  • Key:NPYOTZAJIONLKZ-UHFFFAOYSA-N

PTI-1 (SGT-48) is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4]

See also[edit]

References[edit]

  1. ^ "PTI-1". Cayman Chemical. Retrieved 8 July 2015.
  2. ^ US 7700634, Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR, "(Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor.", issued 20 April 2010, assigned to Organon NV 
  3. ^ US 7763732, Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T, "Indole Derivatives", issued 27 July 2010, assigned to Organon NV 
  4. ^ Kiyoi T, Adam JM, Clark JK, Davies K, Easson AM, Edwards D, et al. (March 2011). "Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists". Bioorganic & Medicinal Chemistry Letters. 21 (6): 1748–53. doi:10.1016/j.bmcl.2011.01.082. PMID 21316962.